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Abstract
Aims/hypothesis Type 2 diabetes mellitus is associated with
moderate decrements in cognitive functioning, mainly in
verbal memory, information-processing speed and execu-
tive functions. How this cognitive profile evolves over time
is uncertain. The present study aims to provide detailed
information on the evolution of cognitive decrements in
type 2 diabetes over time.
Methods Sixty-eight patients with type 2 diabetes and 38
controls matched for age, sex and estimated IQ performed
an elaborate neuropsychological examination in 2002–2004
and again in 2006–2008, including 11 tasks covering five
cognitive domains. Vascular and metabolic determinants
were recorded. Data were analysed with repeated measures
analysis of variance, including main effects for group, time
and the group×time interaction.
Results Patients with type 2 diabetes showed moderate
decrements in information-processing speed (mean differ-
ence in z scores [95% CI] −0.37 [−0.69, −0.05]) and
attention and executive functions (−0.25 [−0.49, −0.01])
compared with controls at both the baseline and the 4 year
follow-up examination. After 4 years both groups showed a
decline in abstract reasoning (−0.16 [−0.30, −0.02]) and
attention and executive functioning (−0.29 [−0.40, −0.17]),
but there was no evidence for accelerated cognitive decline
in the patients with type 2 diabetes as compared with
controls (all p>0.05).
Conclusions/interpretation In non-demented patients with
type 2 diabetes, cognitive decrements are moderate in size
and cognitive decline over 4 years is largely within the
range of what can be viewed in normal ageing. Apparently,
diabetes-related cognitive changes develop slowly over a
prolonged period of time.
Keywords Cognitivedecline.Dementia.Diabetes
mellitus.Longitudinal
Abbreviations
BDI-II Beck Depression Inventory, 2nd edition
TICS-m Modified Telephone Interview for Cognitive
Status
WAIS-III Wechsler Adult Intelligence Scale, 3rd edition
Introduction
The global prevalence of diabetes is expected to rise from
171 million persons in 2000 to 366 million in 2030 [1].
Prevalence estimates for dementia rise from 24 million in
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DOI 10.1007/s00125-009-1571-92001 to 84 million in 2040 [2]. There is compelling
evidence for a link between diabetes and dementia,
particularly in persons over 65 years of age. Longitudinal
studies report a 1.5- to twofold increased risk of dementia,
both Alzheimer’s disease or vascular dementia, in individ-
uals with diabetes compared with those without [3].
Numerous cross-sectional studies have reported on
neuropsychological functioning in non-demented patients
with type 2 diabetes mellitus (e.g. [4, 5]). Systematic
reviews of the literature report a cognitive profile of mild to
moderate decrements in cognitive functioning in patients
with type 2 diabetes [6, 7]. These decrements are most
consistently found in information-processing speed, verbal
memory and executive functioning [6, 7], possibly reflect-
ing a diminished ability to efficiently process unstructured
information [8]. It is, however, less clear how these
cognitive decrements evolve over time. Several longitudinal
population-based studies have examined the risk of cogni-
tive decline associated with type 2 diabetes in individuals
who were not demented at baseline, but these studies have
generally included only a limited number of psychometric
tests or applied cognitive screening instruments, such as the
Mini Mental State Examination, that may be criticised for
lack of sensitivity [9, 10]. The present study provides
detailed assessment of the evolution of cognitive decre-
ments in patients with type 2 diabetes over a 4 year period,
relative to control participants, using an elaborate neuro-
psychological examination. We hypothesised that type 2
diabetes is associated with accelerated cognitive decline.
Methods
Participants The baseline examination (2002–2004) in-
cluded 122 patients with type 2 diabetes and 56 control
participants aged between 56 and 80 years, matched on age,
sex and estimated IQ [8, 11]. Patients were recruited
through general practitioners in the region. Control partici-
pants were recruited among the spouses or acquaintances
of the patients. For inclusion the patients had to have had
type 2 diabetes for at least 1 year, be functionally
independent and Dutch speaking. Exclusion criteria for all
participants were a psychiatric or neurological disorder
(unrelated to diabetes) that could influence cognitive
functioning and a history of alcohol or substance abuse or
dementia. Control participants with a fasting blood glucose
≥7.0 mmol/l were also excluded. At follow-up 4 years later,
seven participants had died, four could not be contacted and
59 were not willing or able to participate. Reasons for not
participatingwere:lackofinterest(n=28); comorbidity (n=22;
three reported dementia [two patients, one control]); and
other reasons (n=9). The remaining 108 participants were
re-examined between 2006 and 2008 (mean follow-up time
4.1±0.4 years). One patient with type 2 diabetes was
excluded because of severe comorbid disease and one
control participant fulfilled the criteria for type 2 diabetes
and was therefore excluded from the control group, leaving
106 participants (68 patients and 38 control participants) in
the present analysis.
The non-participants (n=70) did not differ from the
participants (n=106) with regard to baseline age, sex or
estimated premorbid IQ (all p>0.05). To control for
possible selective loss at follow-up we examined the
cognitive status of both non-participants and participants
(±1 week after their participation in the follow-up exami-
nation) with the Dutch version of the Telephone Interview
for Cognitive Status [12], a 12 item screening instrument
designed to identify persons with dementia [13]. The
Interview was slightly modified (TICS-m) by including a
delayed word-list recall which resulted in a maximum score
of 50 [14]. The TICS-m was obtained from 43 of the 70
non-participants (i.e. 73% of the 59 non-participants who
were still alive and could be contacted) and 99 of the 106
participants (93%). TICS-m scores were normally distrib-
uted across the whole study sample. The TICS-m perfor-
mance for the non-participants was similar to the
participants (non-participants mean score 35.4±5.2, partici-
pants 36.5±4.6, F[1,140]=1.67, p=0.20). Only three
patients with type 2 diabetes (two non-participants, one
participant) and two control participants (one non-
participant, one participant) performed below the cut-off
score of 28 (χ
2[1]=0.24, p=0.62), which is indicative for
cognitive impairment [15]. Hence, among the non-
participants four patients with type 2 diabetes (3% of
baseline sample) and two controls (4% of baseline sample)
had cognitive impairment based on self-reported dementia
or a low TICS-m score (χ
2[1]=0.10, p=0.76). The study
was approved by the medical ethics committee of the
UniversityMedicalCenterUtrecht,Utrecht,theNetherlands.
Written informed consent was obtained from all participants.
Neuropsychological assessment At follow-up all partici-
pants performed an extensive neuropsychological assess-
ment, identical to the baseline examination [8]. Parallel
versions were used for memory tests to control for possible
material-specific learning effects [16]. The neuropsycho-
logical assessment consisted of 11 verbal and non-verbal
tasks, administered in a fixed order that took about 90 min
to complete. The tasks were divided into five cognitive
domains to reduce the amount of neuropsychological
variables in the analysis and for clinical clarity [8]. This
division was made a priori, according to standard neuro-
psychological practice and cognitive theory, as described in
detail in Lezak et al. [16]. The domain ‘abstract reasoning’
was assessed by Raven Advanced Progressive Matrices
(12 item short form). The domain ‘memory’ included four
Diabetologia (2010) 53:58–65 59subdomains: ‘working memory’ assessed by the forward
and backward digit span of the Wechsler Adult Intelligence
Scale, 3rd edition (WAIS-III) and the Corsi Block-tapping
Task (the product scores of the span length×the number of
correctly recalled sequences were recorded [17]); ‘immedi-
ate memory and learning rate’, including verbal memory
assessed by the Rey Auditory Verbal Learning Test and
visual memory assessed by the Location Learning Test;
‘forgetting rate’ assessed by the delayed task of the Rey
Auditory Verbal Learning Test and the Location Learning
Test; and ‘incidental memory’ assessed by the delayed trial
of the modified Taylor Complex Figure. The domain
‘information-processing speed’ was assessed by the Trail-
making Test—Part A, the Stroop Color–Word Test (Parts I
and II), and the subtest Digit Symbol of the WAIS-III. The
domain ‘attention and executive function’ was assessed by
the Trail-making Test—Part B (ratio score), the Stroop
Color–Word Test (Part III; ratio score), the Brixton Spatial
Anticipation Test, a letter fluency test using the ‘N’ and ‘A’,
and category fluency (animal naming). The domain
‘visuoconstruction’ was assessed by the copy trial of the
modified Taylor Complex Figure.
To compare the five different cognitive domains between
the two groups the raw test scores were standardised into z
scores per cognitive domain. These z scores were calculated
by using the pooled mean of baseline scores of the whole
study sample. The z score for each domain was derived by
calculating the mean of the z scores for tests comprising
that domain. Depressive symptoms were assessed with the
Dutch version of the Beck Depression Inventory, 2nd
edition (BDI-II [18]). The total score on this self-rated
depressive symptoms inventory and the proportion of
persons scoring >13 were recorded [19].
Medical history and biometric measurements Procedures at
baseline and follow-up were identical [8]. Medical history
was assessed with a standardised questionnaire addressing
diabetes duration, medication use, history of cardiovascular
disease (including stroke), smoking and alcohol consump-
tion. Fasting glucose, HbA1c and cholesterol levels were
measured with standard laboratory testing. Blood pressure
was measured in a seated position at three time-points
during the half-day visit (Omron MX3; Omron, Mannheim,
Germany). Hypertension was defined as a systolic blood
pressure >160 mmHg, a diastolic blood pressure >95 mmHg
or self-reported use of blood-pressure-lowering medication.
‘Any macrovascular event’ was defined as a history of
myocardial infarction, stroke, or surgery or endovascular
treatment for coronary, carotid or peripheral (legs, abdom-
inal aorta) artery disease. Retinopathy was defined as a
score of ≥1.5 on the Wisconsin Epidemiologic Study of
Diabetic Retinopathy scale [20]. Neuropathy was defined as
Table 1 Baseline characteristics of the patients with type 2 diabetes and the control group
Characteristic Baseline Follow-up
Type 2 diabetes Control group p value Type 2 diabetes Control group p value
n 68 38 – 68 38 –
Age (years) 65.6±5.6 64.8±4.8 0.44 69.8±5.6 68.9±4.8 0.44
Male sex (n) 32 (47%) 19 (50%) 0.77 –– –
Educational level (median (IQR)) 4 (3–5) 4 (4–5) 0.87 –– –
Estimated IQ (points) 100±16 103±13 0.39 97±15 98±15 0.64
Diabetes duration (years) 9.1±6.3 –– – ––
HbA1c (%) 6.9±1.1 5.5±0.3 <0.001 7.2±1.0 5.7±0.4 <0.001
Hypertension
a 49 (72%) 11 (29%) <0.001 53 (78%) 19 (50%) <0.01
BMI (kg/m
2) 27.9±4.0 26.7±5.2 0.19 28.4±4.8 26.7±4.5 0.09
Total cholesterol (mmol/l) 5.0±0.9 5.9±1.2 <0.001 4.5±1.0 5.9±1.0 <0.001
History of stroke 3 (4%) 1 (3%) 0.65 3 (4%) 1 (3%) 0.65
Any macrovascular event
b 18 (27%) 2 (5%) 0.007 20 (29%) 3 (8%) 0.01
Beck Depression Inventory 7.2±5.0 4.4±3.5 0.005 8.5±7.0 5.5±5.1 0.03
Beck Depression Inventory >13 5 (9%) 0 (0%) 0.07 9 (16%) 1 (3%) 0.04
Data are presented as mean ± SD or n (%) unless otherwise specified
aDefined as systolic blood pressure >160 mmHg, diastolic blood pressure >95 mmHg or use of blood-pressure-lowering medication
bDefined as a history of myocardial infarction, stroke, or surgery or endovascular treatment for coronary, carotid of peripheral (legs, abdominal
aorta) artery disease
p values derived using univariate analysis of variance
IQR, interquartile range
60 Diabetologia (2010) 53:58–65a score ≥6 on a modified version of the Toronto Clinical
Neuropathy Scoring System [21, 22].
Statistical analysis Between-group differences in character-
istics were analysed with analysis of variance for continu-
ous variables, Mann–Whitney U tests for non-parametric
data and χ
2 tests for proportions. The primary outcome
measures were the z scores of the five cognitive domains,
which were analysed with repeated-measures ANOVA,
including the effect of time, group and the time×group
interaction. The effect of time reflects the mean change in
cognitive performance over time for the whole study
sample; the effect of group reflects the mean difference
between the patients with type 2 diabetes and the control
group; the time×group interaction reflects the additional
change over time attributable to diabetes status. p values
<0.05 were considered statistically significant.
In a secondary analysis additional adjustment for BDI-II
depressive symptoms was performed to examine a possible
confounding effect of depression. Moreover, within the
diabetes group cognitive functioning (domains information
processing speed and attention and executive functioning)
was compared between patients with high or low baseline
HbA1c (dichotomised at the median level of 6.6 mmol/l),
with or without baseline hypertension and with or without
‘any macrovascular event’ at baseline.
Results
Table 1 shows the characteristics of the patients with type 2
diabetes and the control group at baseline. The groups were
similar in age, estimated IQ and sex distribution. As
expected, between-group differences in glycaemic control,
Test Type 2 diabetes (n=68) Control group (n=38)
Baseline Follow-up Baseline Follow-up
Raven APM (short form) 6.3±2.9 6.3±2.9 7.3±2.1 6.5±2.4
WAIS-III Digit Span
Forward (product score) 45.1±20.5 41.0±20.0 47.6±19.1 48.6±20.6
Backward (product score) 23.1±15.7 21.0±15.0 32.5±23.0 27.5±22.0
Corsi Block-tapping Test
Forward (product score) 38.0±13.8 36.5±11.7 37.8±9.5 37.2±11.3
Backward (product score) 37.1±13.8 37.4±13.6 41.3±12.8 38.8±13.2
Rey Auditory Verbal Learning Test
Total trials 1−5 39.2±9.0 38.4±10.8 43.1±11.4 43.4±10.8
Delayed recall 7.6±2.7 7.7±2.8 8.7±2.8 9.2±3.1
Recognition 28.2±1.9 28.5±1.7 29.1±1.4 29.0±1.5
Location Learning Test
Total trials 1−5
a 24.9±21.0 23.7±22.1 24.8±19.9 20.5±17.1
Learning index 0.59±0.28 0.54±0.31 0.66±0.28 0.61±0.29
Delayed trial
a 2.0±3.3 2.5±3.5 1.7±2.9 1.7±2.8
Complex Figure Test
Copy 32.4±3.9 33.7±2.7 33.0±3.3 33.1±3.0
Delay 17.4±6.6 17.8±6.1 19.9±4.5 18.4±5.2
Stroop Color–Word Test
Part I
a 50.4±12.8 51.2±9.6 47.0±8.9 46.1±7.6
Part II
a 65.1±13.6 66.6±11.6 61.3±14.2 62.8±13.8
Part III
a 124.6±46.6 135.2±46.3 113.1±45.5 118.6±41.5
TMT
Part A
a 49.5±21.0 47.1±22.9 38.6±9.7 38.1±12.1
Part B
a 114.2±44.2 138.0±83.8 89.1±25.1 97.1±30.7
WAIS-III Digit Symbol 54.9±16.8 50.4±15.7 56.6±12.2 56.6±13.5
Verbal fluency
Letter (mean of N+A) 10.4±4.8 9.7±4.2 12.0±4.1 11.1±4.0
Category (Animals) 33.8±10.0 31.4±10.1 34.1±7.7 31.4±10.1
Brixton Spatial Anticipation Test
a 20.8±7.3 22.1±6.3 18.1±6.6 22.1±6.3
Table 2 Raw test scores of the
patients with type 2 diabetes
and the control group at the
baseline and follow-up
examination
Data are mean ± SD
aHigher test scores reflect worse
performance
Raven APM, Raven Advanced
Progressive Matrices; RALVT,
Rey Auditory Verbal Learning
Test; LLT, Location Learning
Test; TMT, Trail-making Test
Diabetologia (2010) 53:58–65 61vascular risk factors and vascular events were still present
at the follow-up examination after 4 years. At baseline six
(9%) patients were treated with diet only, 42 (62%) used
oral glucose-lowering medication and 20 (29%) used
insulin. The baseline prevalence of retinopathy and neu-
ropathy was 32% and 35%, respectively.
Table 2 shows the raw test scores of the neuropsycho-
logical examination for both groups at baseline and
follow-up. To limit the number of comparisons, only the
differences in domain scores were compared statistically
(Table 3). As is shown in Fig. 1 the results of the repeated-
measures ANOVA demonstrated a significant decline in
performance over 4 years for the whole sample on the
domains abstract reasoning and attention and executive
functions (mean change in z scores −0.16, F[1,93]=4.83,
p=0.03 and −0.29, F[1,103]=25.59, p<0.001, respective-
ly). A significant main effect of group was found in
information-processing speed (mean difference in z scores
for patients with type 2 diabetes compared with controls:
−0.37, F[1,102]=6.68, p<0.05) and attention and executive
functions (−0.25, F[1,103]=3.01, p<0.05), and a trend in
the same direction on memory (−0.16, F[1,103]=3.42,
p=0.07). There were no significant time×group interactions,
although there was a trend towards interaction for visuo-
construction (p=0.07). Additional adjustment for BDI-II
score or exclusion of persons with a BDI-II score >13 did
not change the results. Visual inspection of the distribution
of the individual z scores for each domain did not reveal
differences between the diabetes group and the control
group. This indicated that it was the diabetes group as a
whole that had a worse mean performance, rather than a
subgroup of patients with type 2 diabetes performing in the
lowest part of the z score distribution.
In secondary analyses within the diabetes group no
significant group differences or time×group interactions with
regard to HbA1c level were found (information-processing
speed mean group difference [95% CI]=0.07 [−0.37, 0.51];
attention and executive functions −0.08 [−0.38, 0.23]) or the
presence of hypertension (information-processing speed 0.11
[−0.38, 0.60]; attention and executive functions 0.01 [−0.33,
0.34]). For patients with type 2 diabetes with ‘any macro-
vascular event’ there was a trend toward a worse perfor-
mance on information-processing speed (−0.46 [−0.95,
0.03]), but no differences were found on attention and
executive functions (−0.19 [−0.53, 0.15]).
Discussion
Patients with type 2 diabetes showed moderate decrements
in cognitive functioning compared with control participants
matched for age, sex and estimated IQ, both at baseline and
after 4 year follow-up in the information-processing speed
and attention and executive functioning domains. After
4 years a decline in abstract reasoning and attention and
executive functioning was found for the whole sample, but
no evidence was shown for accelerated decline in the
patients with type 2 diabetes.
The profile of cognitive decrements and the size of the
effects observed in the present study are comparable with
the results from previous cross-sectional studies on cogni-
tion in type 2 diabetes, which show small to moderate
decrements (effect sizes −0.3 to −0.6) particularly in the
domains information-processing speed, executive function-
ing and memory [6]. Interestingly, the effect sizes of cross-
sectional studies in patients with different stages of type 2
diabetes or even prediabetic stages are remarkably similar,
generally ranging from −0.3 to −0.6 [4, 23–25], indicating
that these decrements may develop in the early stage of the
disease and progress only gradually thereafter. Our findings
on the domain visuoconstruction were dissimilar to the
other domains, as the performance of the patients with
type 2 diabetes tended to improve. We have no certain
explanation for this observation, but the fact that this
Table 3 Differences in cognitive domain scores for patients with type 2 diabetes and the control group at the baseline and follow-up examination
Domains Mean change
over time
a
Mean difference between
T2DM and control group
b
Time×group interaction
p value
Abstract reasoning −0.16 (−0.30 to −0.02) −0.17 (−0.57 to 0.22) 0.20
Memory −0.06 (−0.14 to 0.02) −0.16 (−0.34 to 0.01) 0.15
Information-processing speed −0.05 (−0.14 to 0.04) −0.37 (−0.69 to −0.05) 0.23
Attention and executive functions −0.29 (−0.40 to −0.17) −0.25 (−0.49 to −0.01) 0.37
Visuoconstruction 0.16 (−0.06 to 0.38) −0.06 (−0.36 to 0.24) 0.07
Data are z scores (95% CI) analysed with repeated-measures analysis of variance
aFor the whole sample
bControl group is reference
T2DM, type 2 diabetes mellitus
62 Diabetologia (2010) 53:58–65domain only comprised a single test, in contrast to the other
domains, may have affected the reliability of this domain
score and increased the potential impact of confounding
factors such as motivation, ceiling effects or practice
effects, particularly for those participants with an initial
worse performance.
To date, longitudinal studies that examine the cognitive
profile of patients with type 2 diabetes and control
participants by means of a detailed neuropsychological test
battery are scarce. Two previous case–control studies, with
smaller samples of patients with type 2 diabetes than the
present study, did not consistently observe accelerated
cognitive decline in patients with type 2 diabetes after a 3
to 4 year follow-up [26, 27]. Longitudinal population-based
studies, which included less detailed assessment of cogni-
tive functioning than the present study, showed moderate
differences in cognitive performance between patients with
type 2 diabetes and controls at baseline and follow-up [9,
10, 28, 29], similar to the differences found in the present
study. Some of these studies also observe a modest
accelerated decline after a 3 to 6 year period on a subset
of the cognitive measures [9, 10, 29] of approximately 1.5
times the decline of the non-diabetic participants. Appar-
ently, no marked accelerated cognitive decline is found in
the majority of patients with type 2 diabetes relative to
persons without type 2 diabetes. This is in contrast with
prototypic diabetic complications, such as retinopathy,
nephropathy and neuropathy, for which prevalence and
severity clearly increase with duration of diabetes and
exposure to elevated glucose levels. Future aetiological
studies should answer the question why cognitive decre-
ments can already be found in prediabetic stages, or at the
time of diabetes diagnosis, and progress only slowly
thereafter. In prediabetic stages exposure to vascular risk
factors such as hypertension, dyslipidaemia and obesity
may play a role. Although acute effects of elevated blood
glucose levels on cognitive functioning have been reported
[30], the present findings suggest that long-term exposure
to elevated blood glucose levels apparently do not have a
major impact on cognition in patients with type 2 diabetes,
a finding in line with recent observations in adult patients
with type 1 diabetes [31].
The question also is how these findings relate to the 1.5-
to twofold increased risk of dementia that is observed in
individuals with type 2 diabetes [3]. A likely explanation is
that the subtle cognitive decrements that are found in non-
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Fig. 1 Cognitive functioning (mean standardised domain score ±
SEM) for the patients with type 2 diabetes (white circles; n=68) and
the control group (black circles; n=38) at baseline (BL) and 4 year
follow-up (FU): a abstract reasoning, main effect of time p=0.03,
main effect of group p=0.39, time×group interaction p=0.20;
b memory, main effect of time p=0.16, main effect of group p=0.07,
time×group interaction p=0.15; c information-processing speed, main
effect of time p=0.28, main effect of group p=0.02, time×group
interaction p=0.23; d attention and executive functioning, main effect
of time p<0.001, main effect of group p=0.04, time×group
interaction p=0.37; e visuoconstruction, main effect of time p=0.15,
main effect of group p=0.71, time×group interaction p=0.07. p values
indicate the results of the repeated-measures ANOVA
Diabetologia (2010) 53:58–65 63demented populations do not necessarily evolve into frank
cognitive decline in all individuals, but rather that within
the population of older patients with type 2 diabetes, severe
cognitive decline only occurs in a subgroup of persons,
possibly in interaction with other risk factors such as the
apolipoprotein E status [32], hypertension [33]o rt h e
metabolic syndrome [34]. Furthermore, particularly below
the age of 70 years, incident dementia is relatively rare
(annual incidence <1% per year [35]). This makes dementia
a fundamentally different cognitive outcome measure than
the more subtle cognitive decrements that are addressed in
the present study, which show a normal distribution across
the whole study sample.
The present detailed analysis of the neuropsychological
profile associated with type 2 diabetes revealed a pattern of
modest decrements in information-processing speed and
attention and executive functioning, with a non-significant
trend in the same direction for memory. This profile appears
to reflect an overall diminished performance level rather
than deficits in specific cognitive functions [36]a n d
resembles the pattern that is found in normal ageing [36].
The principal strength of the present study is the detailed
neuropsychological examination that was performed twice
over a 4 year interval in a relatively large sample of patients
with type 2 diabetes. Limitations include possible selection
bias due to selective attrition during the follow-up period.
The results of the TICS-m showed that selection bias due to
drop out of persons with severely impaired cognitive
functioning was limited. Nevertheless, during follow-up of
the non-participants we observed that several persons with
marked cognitive decline dropped out of the study, albeit at
a low rate that was similar in the two groups. Moreover, the
reduction in sample size at the follow-up examination may
have limited the power of the statistical analyses, particu-
larly with regard to the time×group interactions.
In summary, the results of the present study indicate that
in functionally independent patients with type 2 diabetes
cognitive decrements are modest in size and decline is
largely within the range of what can be viewed in normal
ageing. Apparently, diabetes-related cognitive changes
progress slowly over a prolonged period of time, probably
much longer than the 4 years of follow up in the present
study.
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